Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06896916
Recruiting
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 · Australia, Canada, France, Japan, Netherlands, Norway, United States · 28 sites
Registry update: 12 May 2026
NCT07763054
Recruiting
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Not applicable · China · 1 site
Registry update: 13 Aug 2026
NCT07073547
Recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Phase 1 · United States · 13 sites
Registry update: 25 Sept 2026
NCT07652138
Recruiting
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Phase 1 · China · 1 site
Registry update: 16 Jun 2026
NCT06348108
Recruiting
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 13 Mar 2026
NCT07099391
Recruiting
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Phase 1/2 · United States · 7 sites
Registry update: 2 Nov 2026
NCT06953960
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 · Australia, Belgium, Germany, France, United Kingdom, Israel, Italy, Japan, Poland, Portugal, Sweden, United States · 56 sites
Registry update: 27 Oct 2026
NCT06730256
Recruiting
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Early phase 1 · China · 1 site
Registry update: 1 Oct 2025
NCT07075185
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1 · Australia, United States · 11 sites
Registry update: 28 Aug 2026
NCT07180992
Recruiting
Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
Not applicable · France · 1 site
Registry update: 18 Nov 2025
NCT07296627
Recruiting
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Not applicable · China · 1 site
Registry update: 22 Dec 2025
NCT07051850
Recruiting
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Not applicable · South Korea · 1 site
Registry update: 15 Jul 2025
NCT06918002
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Phase 3 · Belgium, France · 66 sites
Registry update: 30 Sept 2026
NCT07312188
Recruiting
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 31 Dec 2025
NCT07239323
Recruiting
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · China · 1 site
Registry update: 4 Nov 2026
NCT06892522
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Phase 1/2 · Australia, United Kingdom, Israel, Japan, Norway, United States · 36 sites
Registry update: 19 Oct 2026
NCT07045909
Recruiting
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
Phase 2 · Spain · 10 sites
Registry update: 1 Aug 2025
NCT07771803
Recruiting
A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Early phase 1 · United States · 1 site
Registry update: 18 Aug 2026
NCT07283224
Recruiting
Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
Not applicable · Italy · 1 site
Registry update: 12 May 2026
NCT07305337
Recruiting
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
Not applicable · China · 1 site
Registry update: 26 Dec 2025

Ordered by registry start date. Freshness and sponsorship never change the order.